Genetic Disease Risk for IVF Babies in Georgia: PGT Screening and Genetic Testing Process Explained

Real Consultation Scenario: A Real Question from a Woman Carrying an Autosomal Dominant Genetic Mutation

During an outpatient consultation, a 42-year-old woman presented an exome sequencing report showing she carries a heterozygous mutation in the MYH9 gene (associated with hereditary thrombocytopenia). She had already completed one fresh embryo transfer at a reproductive center in Georgia, and 14 days later, β-hCG was negative. She asked: “If I continue with IVF in Georgia, will my baby inherit my disease? Can the laboratory in Georgia detect this mutation of mine?”

This patient’s question is very specific: whether the reproductive center in Georgia has the capability to perform preimplantation genetic testing for monogenic diseases (PGT-M), and whether local regulations allow screening for known pathogenic mutations. The reality is: Georgia allows third-generation IVF (PGT), but the scope and accuracy of genetic testing vary greatly between different centers. Below, we break down the mechanisms, processes, preparations, and risk control step by step.

Possibility of Genetic Diseases in IVF Babies in Georgia

Core Logic of Genetic Disease Transmission

Whether an IVF baby develops a genetic disease depends on three factors:

• Parents' genetic material: Chromosomal number/structural abnormalities, single-gene pathogenic mutations, mitochondrial disease carrier status.
• Method of embryo formation: Natural fertilization or ICSI itself does not change genetic risk, but if donor eggs/sperm are used, pathogenic mutations carried by the donor will also be transmitted.
• Whether embryo genetic testing is performed: Embryos without PGT have the same genetic disease risk as naturally conceived embryos; embryos with PGT can significantly reduce the transmission probability of specific genetic diseases, but cannot 100% rule out mosaicism or missed detection due to technical limitations.

Differences in PGT Capabilities Among Different Hospitals in Georgia

There are about 10 officially licensed assisted reproduction institutions in Georgia, and even fewer have independent genetic laboratories. Common differences are as follows:

Note: Even if an institution claims to offer PGT-M, it is necessary to confirm whether it has the capability for probe design and Sanger sequencing verification targeting the patient's specific mutation site. Some institutions only provide basic PGT-A and are unable to handle monogenic diseases.

How Doctors Assess Genetic Risk and Develop a PGT Plan

Assessment Process

1. Step 1: Genetic Counseling: Collect family history from both sides, history of miscarriage or illness, ethnic background (e.g., Ashkenazi Jewish population is recommended for Tay-Sachs disease screening).
2. Step 2: Carrier Screening for Both Partners: Expanded carrier screening (ECS) covering 300+ common recessive genetic diseases is recommended. Institutions in Georgia usually send samples to European partner laboratories (e.g., Germany, Czech Republic), and results take 2-3 weeks.
3. Step 3: Choose PGT Mode: If a high-risk mutation is found, confirm with the embryologist whether single-cell linkage analysis or direct mutation detection can be designed.
4. Step 4: Sign Informed Consent: The limitations of PGT must be clearly stated—it is not responsible for untested loci, and there is a possibility of misdiagnosis due to embryo biopsy failure, amplification failure, or mosaicism.

When is PGT-M Not Suitable in Georgia?

• The pathogenic gene locus is extremely rare (only a few cases reported worldwide), making it impossible to design and verify probes within a reasonable time.
• The mutation is located in a highly repetitive region or a region with extremely high GC content, resulting in sequencing accuracy below 90% after single-cell whole genome amplification.
• The patient is aged ≥45 years with ≤2 oocytes retrieved; there may be no usable embryos after biopsy. Donor eggs or embryos should be considered as a priority.

Actual Process and Required Materials

Timeline (from initial consultation to transfer)

• Weeks 1-2: Genetic counseling + blood sample collection from both partners (EDTA anticoagulant tubes, 2ml each), sent for carrier screening.
• Weeks 3-5: Wait for screening report; simultaneously perform female fertility assessment (AMH, antral follicle count), male semen analysis, and chromosomal karyotyping for both partners.
• Weeks 5-7: If a clear pathogenic mutation is found, communicate with the laboratory about probe design; the design cycle is about 3-6 weeks, requiring additional time.
• Weeks 8-12: Enter ovulation stimulation cycle, perform ICSI after egg retrieval, culture embryos to blastocyst stage (day 5/6) for biopsy.
• Weeks 9-13: Biopsied cells undergo whole genome amplification and are sent for PGT; results return in about 10-14 working days.
• Weeks 10-15: Select transferable embryos (normal or balanced carriers) based on PGT results, and proceed with a frozen-thawed embryo transfer cycle.

Required Materials

• Original passports of both partners (validity must cover the entire cycle; it is recommended to have at least 6 months remaining)
• Original genetic reports from both partners and Chinese translations (if carrier screening or whole exome sequencing was done at another hospital)
• ID cards of both partners (some institutions require them for registration)
• Genetic testing report of previous miscarriage tissue (if available, can help determine if it is a de novo mutation)
• Infectious disease screening reports (HIV, Hepatitis B, Hepatitis C, Syphilis; valid for 6 months)

Easily Overlooked Details and Pitfalls

Detail 1: Regulatory Restrictions on PGT-M in Georgian Institutions

Georgian law allows genetic diagnosis of embryos to screen for healthy embryos, but does not allow screening for non-medical characteristics (e.g., sex selection, unless for sex-linked genetic diseases). Some institutions interpret the regulations more loosely, so patients need to confirm for themselves.

Detail 2: Missed Detection Due to Embryo Mosaicism

PGT biopsy takes trophectoderm cells (cells that will form the placenta). If the inner cell mass (which will develop into the fetus) is inconsistent with the trophectoderm cells (mosaicism), the PGT result may not reflect the true genetic status of the fetus. The probability of this occurring is about 1%-3%, and subsequent prenatal diagnosis via amniocentesis is required for confirmation.

Detail 3: Lack of Local Genetic Laboratory Linkage Analysis Verification in Georgia

Large domestic reproductive centers typically perform linkage analysis verification using blood samples from the couple and the previous generation after probe design to ensure detection accuracy. Most Georgian institutions outsource genetic testing. If the outsourcing laboratory cannot quickly obtain family samples for verification, the reliability of the probe may decrease.

Detail 4: Genetic Material Stability of Frozen Embryos

Embryos after PGT need to be cryopreserved. Do biopsied cells maintain an intact genome after thawing? In fact, freezing does not affect DNA integrity, but if the embryo is damaged during the thawing process, it may affect subsequent transfer success (unrelated to genetic diseases).

Applicability and Risk Differences for Different Age Groups

Women Under 35

The natural incidence of chromosomal aneuploidy is about 2%-3%. If neither partner has a clear family history of genetic diseases, PGT-A is generally not necessary. However, if the woman carries a recessive pathogenic gene (e.g., GJB2 deafness gene), PGT-M should be seriously considered.

Women Aged 35-40

The oocyte aneuploidy rate increases to 15%-30%. PGT-A can significantly improve transfer efficiency, but note: embryos with normal PGT-A results still have a 1%-2% risk of genetic diseases (single gene or microdeletion/duplication). Carrier screening is recommended simultaneously.

Women Over 40

The chromosomal abnormality rate exceeds 50%. Even if PGT-A selects euploid embryos, the live birth rate is still limited by oocyte quality. A more common issue in this age group is: due to decreased oocyte integrity from advanced age, insufficient cell numbers after embryo biopsy may lead to PGT result failure. Alternative: accumulate oocytes from multiple cycles before undergoing PGT.

Frequently Asked Questions

Q: If an IVF baby in Georgia is born with a genetic disease, is the hospital responsible?

Under normal circumstances, the hospital is only responsible for the quality of the embryo manipulation process and does not assume responsibility for the occurrence of genetic diseases—because PGT technology itself has a probability of missed detection that cannot be 100% avoided, and genetic diseases may be caused by de novo mutations during embryo development. It is recommended that patients carefully read the disclaimer before signing the informed consent form.

Q: If the father carries a genetic disease mutation, does he need to come to Georgia for PGT-M?

No. The male partner's blood can be collected at a local hospital and sent to the partner laboratory in Georgia via international cold chain logistics. However, note: customs has strict regulations on the import and export of blood products, and a professional biological sample transport company must be used.

Q: How much does PGT cost in Georgia?

PGT-A costs about $800-$1,200 per embryo; PGT-M costs about $1,500-$2,500 per embryo (including probe design fees of about $1,000-$2,000). The total cost usually includes ovulation stimulation, egg retrieval, laboratory culture, and one frozen-thawed transfer cycle, ranging from $12,000 to $20,000, depending on the institution's tier and medication brand.

Risk Reminder

This content does not constitute medical advice. Genetic risk assessment must be comprehensively evaluated by a reproductive genetics specialist based on complete genetic test reports, family history, and chromosomal karyotype results. PGT technology can only reduce the transmission risk of specific genetic diseases and cannot eliminate all genetic defects. Before any embryo transfer, patients are advised to seek a second confirmation at a major genetic counseling center domestically, especially regarding whether the PGT-M probe design for monogenic diseases aligns with Chinese clinical genetics consensus. There are differences in testing standards and quality control systems between Georgian institutions and domestic institutions; thorough research should be conducted before making a decision.